External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: Impact of pretreatment PSA value on radiotherapeutic outcomes

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 372-379

  Akimoto, Tetsuo ^a,d   Kitamoto, Yoshizumi ^a   Saito, Jun Ichi ^a   Harashima, Koichi ^a   Nakano, Takashi ^a   Ito, Kazuto ^a   Yamamoto, Takumi ^a   Kurokawa, Kouhei ^a   Yamanaka, Hidetoshi ^a   Takahashi, Mitsuhiro ^b   Mitsuhashi, Norio ^c   Niibe, Hideo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Kiryu Kosei General Hospital   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

Hormone refractory; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIGENS; BONE; ENZYMES; HORMONES; RADIOTHERAPY; RISK ASSESSMENT; TUMORS;

EXTERNAL BEAM RADIOTHERAPY (EBRT); PROSTATE-SPECIFIC ANTIGEN (PSA); SURVIVAL RATES;

ONCOLOGY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BONE METASTASIS; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE DURATION; FOLLOW UP; HORMONAL REGULATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; SURVIVAL RATE;

EID: 2442426394     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.033     Document Type: Article

References (31)

1. Kolvenbag G.J., Iversen P., Newling D.W. Antiandrogen monotherapy A new form of treatment for patients with prostate cancer. Urology. 58:(2 Suppl. 1):2001;16-23
2. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer 6.3 years of followup. J Urol. 164:2000;1579-1582
3. Egawa S., Go M., Kuwao S., et al. Long-term impact of conservative management on localized prostate cancer A twenty-year experience in Japan. Urology. 42:1993;520-527
4. Kotake T., Usami M., Akaza H., et al. Zoladex Study Group. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer A multicenter, randomized, controlled trial in Japan. Jpn J Clin Oncol. 29:1999;562-570
5. De La Taille A., Vacherot F., Salomon L., et al. Hormone-refractory prostate cancer A multi-step and multi-event process. Prostate Cancer Prostatic Dis. 4:2001;204-212
6. Roth B.J. New therapeutic agents for hormone-refractory prostate cancer. Semin Oncol. 23:(6 Suppl. 14):1996;49-55
7. Lankford S.P., Pollack A., Zagars G.K. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys. 33:1995;907-912
8. Kurokawa K., Ito K., Suzuki K., et al. Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy Is it possible to identify patients likely to have good treatment outcomes? Jpn J Clin Oncol. 32:2002;466-471
9. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031
10. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13
11. Wang J.Z., Guerrero M., Li X.A. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 55:2003;194-203
12. Jones B., Dale R.G., Finst P., et al. Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;1379-1384
13. Orton C.G. High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells. Int J Radiat Oncol Biol Phys. 49:2001;183-189
14. American Society for Therapeutic Radiology and Oncology, Hanlon A.L., Hanks G.E. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys. 46:2000;559-566
15. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346
16. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-481
17. Cox D.R. Regression model and life table. J R Stat Soc. 34:1972;187-220
18. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 49:2001;947-956
19. Shipley W.U., Lu J.D., Pilepich M.V., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys. 54:2002;1302-1310
20. Murillo H., Huang H., Schmidt L.J., et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 142:2001;4795-4805
21. Franke T.F., Kaplan D.R., Cantley L.C. PI3K Downstream AKTion blocks apoptosis. Cell. 88:1997;435-437
22. Krasilnikov M., Adler V., Fuchs S.Y., et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog. 24:1999;64-69
23. Chang F., Lee J.T., Navolanic P.M., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation A target for cancer chemotherapy. Leukemia. 17:2003;590-603
24. King C.R., DiPetrillo T.A., Wazer D.E. Optimal radiotherapy for prostate cancer Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 46:2000;165-172
25. Furuya Y., Akakura K., Akimoto S., et al. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol. 6:1999;187-191
26. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221
27. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 76:2001;576-581
28. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 19:2001;1030-1039
29. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101
30. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 41:1998;83-92
31. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 53:2002;1111-1116